Aflibercept for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Sarwar, Salman ^a   Clearfield, Elizabeth ^b   Soliman, Mohamed Kamel ^a   Sadiq, Mohammad Ali ^a   Baldwin, Andrew J ^a   Hanout, Mostafa ^a   Agarwal, Aniruddha ^a   Sepah, Yasir J ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PLACEBO; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; ARTERY THROMBOSIS; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEART INFARCTION; HUMAN; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA HEMORRHAGE; REVIEW; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; VISION; VISUAL ACUITY; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; MACULAR DEGENERATION; META ANALYSIS;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VISUAL ACUITY;

EID: 84969584507     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011346.pub2     Document Type: Review

References (62)

1. Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology 2015;122(9):1802-10.
2. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48.
3. Mitchell P, VIEW Study Group. Intravitreal aflibercept versus ranibizumab for neovascular age-related macular degeneration: 52-week subgroup analyses from the combined VIEW studies. Clinical and Experimental Ophthalmology 2012;40(Suppl 1):41-56.
4. Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology 2015;122(12):2497-503.
5. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology 2014;121(1):193-201.
6. Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 2015;122(4):822-32.
7. Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, et al. Improvement in vision-related function with intravitreal aflibercept. Data from phase 3 studies in wet age-related macular degeneration. Ophthalmology 2015;122(3):571-8.
8. Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology 2015;122(9):1802-10.
9. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48.
10. Mitchell P, VIEW Study Group. Intravitreal aflibercept versus ranibizumab for neovascular age-related macular degeneration: 52-week subgroup analyses from the combined VIEW studies. Clinical and Experimental Ophthalmology 2012;40(Suppl 1):41-56.
11. Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, et al. Efficacy and safety of intravitreal aflibercept injection in wet-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. British Journal of Ophthalmology 2015;99(1):92-7.
12. Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology 2015;122(12):2497-503.
13. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology 2014;121(1):193-201.
14. Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 2015;122(4):822-32.
15. Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, et al. Improvement in vision-related function with intravitreal aflibercept. Data from phase 3 studies in wet age-related macular degeneration. Ophthalmology 2015;122(3):571-8.
16. Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113(9):1522.e1-14.
17. Elshout M, van de Reis MI, Webers CA, Schouten JS. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(12):1911-20.
18. Yoshida I, Shiba T, Taniquchi H, Takahashi M, Murano T, Hiruta N, et al. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2014;252(9):1483-9.
19. Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmologica 2015;93(2):e154-9.
20. Zinkernagel MS, Schorno P, Ebneter A, Wolf S. Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant. Investigative Ophthalmology & Visual Science 2015;56(3):1894-900.
21. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015. www.aao.org/ppp.
22. Age-Related Eye Disease Study Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS report no. 14. Archives of Ophthalmology 2005;123(9):1207-14.
23. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Survey of Ophthalmology 1995;39(5):367-74.
24. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1432-44.
25. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011;118(6):1089-97.
26. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011;364(20):1897-908.
27. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010;10:31.
28. Childs AL, Bressler NM, Bass EB, Hawkins BS, Mangione CM, Marsh MJ, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings: SST Report No. 14. Ophthalmology 2004;111(11):2007-14.
29. Clemons TE, Chew EY, Bressler SB, McBee W. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Archives of Ophthalmology 2003;121(2):211-7.
30. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
31. Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, et al. Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology 2012;119(4):771-8.
32. Dong LM, Childs AL, Mangione CM, Bass EB, Bressler NM, Hawkins BS, et al. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST Report No. 4. American Journal of Ophthalmology 2004;138(1):91-108.
33. US Food, Drug Administration. FDA news release (2011): FDA approves Eylea for eye disorder in older people. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm (accessed 16 December 2013).
34. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. European Cytokine Network 2009;20(4):158-63.
35. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Archives of Ophthalmology 1986;104(4):513-4.
36. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004;122(4):564-72.
37. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013;120(5 Suppl):S3-7.
38. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118(6):1098-106.
39. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48.
40. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
41. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America 2002;99(17):11393-8.
42. Hyman L, Neborsky R. Risk factors for age-related macular degeneration: an update. Current Opinion in Ophthalmology 2002;13(3):171-5.
43. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382(9900):1258-67.
44. Jansen RM. The off-label use of medication: the latest on the Avastin - Lucentis debacle. Medicine and Law 2013;32(1):65-77.
45. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. American Journal of Ophthalmology 1999;128(1):45-53.
46. Miskala PH, Bass EB, Bressler NM, Childs AL, Hawkins BS, Mangione CM, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST Report No. 12. Ophthalmology 2004;111(11):1981-2.
47. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Current Medical Research and Opinion 2011;27(7):1465-75.
48. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2]
49. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
50. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1419-31.
51. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proceedings of the National Academy of Sciences of the United States of America 2007;104(47):18363-70.
52. Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. British Journal of Ophthalmology 2015;99(2):141-6.
53. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Current Opinion in Ophthalmology 2010;21(3):218-26.
54. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard. PloS One 2012;7(8):e42701.
55. Schultz DW, Klein ML, Humpert AJ, Luzier CW, Persun V, Schain M, et al. Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Human Molecular Genetics 2003;12(24):3315-23.
56. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3]
57. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. British Journal of Ophthalmology 2008;92(5):667-8.
58. Thomas M, Mousa SS, Mousa SA. Comparrative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clinical Opthahalmology 2013;7:495-501.
59. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye 2005;19(9):935-44.
60. Wong TY, Chakravarthy U, Kelin R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115(1):116-26.
61. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health 2014;2(2):e106-16.
62. Sarwar S, Maya JR, Hanout M, Sepah YJ, Do DV, Nguyen QD. Aflibercept for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD011346]